Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesObstetrics/GynecologyAetna chronic pelvic pain coverage & prior auth | …
    Ask Trek AI about this page
    CurrentAetnaPolicy 0754

    Chronic Pelvic Pain, Endometriosis, and Other Indications: Selected Treatments

    Customize your policy alerts

    Sign up for Aetna Policy 0754 alerts

    Get alerted when Policy 0754 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for select procedures used to treat chronic pelvic pain, endometriosis, and related indications for commercially insured members and providers submitting claims to Aetna.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerAetna
    PolicyChronic Pelvic Pain, Endometriosis, and Other Indications: Selected Treatments
    Policy CodePolicy 0754
    Change TypeNo material change
    Effective DateMay 9, 2008
    Last ReviewOct 5, 2023
    Next Review DateAug 8, 2024
    Key ActionDocument trial and failure of conservative therapies (medical therapy, physical therapy, behavioral interventions) before requesting surgical or device-based interventions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    15-20%women 18-50 with chronic pelvic pain
    4procedures experimental/investigational
    487subjects in large LUNA RCT
    15% vs 41%PN vs control treatment failure
    12.5%post-op constipation with PN
    10/05/2023last reviewed

    Coverage Criteria and Evidence Summary

    Coverage rationale and evidence-based criteria

    Coverage stance and evidence summary for nerve interruption and selected procedures:

    Experimental/Investigational Procedures: The following procedures are considered experimental and investigational because effectiveness has not been established: dorsal root ganglion stimulation; hypogastric plexus neurolysis for chronic pelvic pain associated with endometriosis; peritoneal excision (stripping) for the treatment of endometriosis; uterine nerve ablation (UNA)/laparoscopic uterine nerve ablation (LUNA); presacral neurectomy (PSN; open and laparoscopic).

    Policy lists these procedures as experimental/investigational

    Evidence on LUNA and PSN: Randomized trials and systematic reviews show limited or inconsistent benefit for LUNA; presacral neurectomy (PSN) may improve midline dysmenorrhea in some trials but is associated with higher adverse events (eg, constipation, urinary urgency). Methodologically sound, sufficiently powered RCTs are needed to assess effectiveness for chronic pelvic pain.

    Cochrane and other systematic reviews; Daniels et al RCT; Proctor et al 2005

    Medical and conservative management before surgical nerve interruption: Initial management should include conservative medical therapy (NSAIDs, oral contraceptives) and second-line pharmacologic options (eg, danazol, GnRH analogs); conservative surgical approaches (excision/ablation of implants, adhesiolysis) are standard before considering more invasive nerve interruption procedures such as LUNA or PSN.

    Guidelines and expert panels recommend conservative-first approach

    Adjunctive Presacral Neurectomy (PN) for Midline Endometriosis-related Pain

    Evidence summary and patient selection considerations

    Eligibility considerations: Adjunctive presacral neurectomy (PN) may provide greater relief from midline pelvic pain when added to conservative endometriosis surgery in well-selected patients; however, evidence is derived mainly from older, lower-quality studies and PN increases the risk of postoperative constipation. Consider PN only after failure of conservative medical therapy and conservative surgery and when pain is clearly midline and refractory.evidence variable

    Meta-analysis: treatment failure 15.0% with PN vs 40.9% controls; post-op constipation 12.5%

    Peritoneal excision (stripping) and excision/ablation of superficial endometriosis

    Guidance based on RCTs and guideline statements

    Indications: Excision or ablation of symptomatic superficial peritoneal endometriosis is recommended for patients with pelvic pain; surgical treatment of asymptomatic superficial lesions is not recommended. Excision is preferred over ablation in infertile women when evidence suggests higher spontaneous pregnancy rates with excision.symptomatic status

    RCTs report substantial pain reduction versus no surgery; CNGOF guidance favors excision in selected infertile patients

    Uterosacral nerve ablation (LUNA) and other nerve-dividing procedures

    Evidence and recommendations

    Stance: Laparoscopic uterosacral nerve ablation (LUNA) is not shown to be effective for chronic pelvic pain related to endometriosis; routine use of uterosacral nerve ablation or other nerve-dividing procedures is not supported by available evidence. Presacral neurectomy may have a role for centrally located dysmenorrhea in select cases but overall evidence is limited and adverse events are more common.evidence negative

    Large RCTs and systematic reviews indicate lack of benefit for LUNA and limited, heterogeneous evidence for nerve-dividing surgery

    Hypogastric plexus neurolysis/blocks

    Evidence primarily in cancer-related pelvic pain; limited evidence for endometriosis-related CPP

    Considerations: Superior/inferior hypogastric plexus blocks or neurolytic procedures have demonstrated pain reduction in cancer-related pelvic pain series; evidence for chronic pelvic pain associated with endometriosis is limited. Consider these interventions only in select refractory non-malignant cases after documented trials of other therapies and when performed in specialized centers; randomized data are lacking.primarily cancer pain evidence

    Single-center series and feasibility studies support use in malignancy but not in endometriosis-related CPP

    Peritoneal excision and adhesiolysis

    Coverage considerations based on symptom status and fertility desire:

    Excision for symptomatic superficial endometriosis: When superficial peritoneal endometriosis is incidentally found in women with pelvic pain, excision of surgically accessible lesions is recommended as it may improve pain and quality of life (low level of evidence).symptomatic

    CNGOF/AGREE II/GRADE-based recommendation

    Not recommended settings: Surgical treatment of asymptomatic superficial peritoneal endometriosis and routine adhesiolysis for incidental, asymptomatic adhesions are not recommended due to lack of evidence of benefit and increased surgical risk; case-by-case exceptions include infertile women with minimal tubo-ovarian adhesions where limited adhesiolysis may be considered.asymptomatic

    Low level of evidence; avoid prophylactic excision/adhesiolysis

    Endometrioma treatment (EST vs laparoscopic surgery)

    Evidence from small trials comparing ethanol sclerotherapy (EST) and laparoscopic surgery:

    Efficacy and ovarian reserve: A randomized trial (n=70) reported similar recurrence rates at 12 months between ethanol sclerotherapy (EST) and laparoscopic surgery; laparoscopy was associated with a significant decrease in AMH levels while EST was not. Small sample size limits generalizability.

    Tehrani et al 2022

    Retrospective comparison outcomes: A retrospective study reported better pregnancy and live-birth rates and fewer complications after EST compared with laparoscopic stripping, but findings are limited by small sample size and retrospective design and require validation.

    Antonaci et al 2022

    Dorsal root ganglion stimulation (DRGS)

    Neuromodulation for refractory chronic pelvic pain:

    Candidate selection: Dorsal root ganglion stimulation (DRGS) may be considered on a case-by-case basis for patients with chronic pelvic pain refractory to non-interventional measures and who are not candidates for other neuromodulation; current evidence is low-quality (Level IV) and further high-quality studies are needed.

    Systematic review of 9 studies, 65 patients; evidence low quality

    Myofascial manual therapies (MMT)

    Physical/manual therapy for chronic pelvic pain syndrome (CPPS):

    Effectiveness: Systematic review and meta-analysis (7 studies, 5 meta-analyzed) found myofascial manual therapies (MMT) were not significantly superior to standard care for pain, symptom impact, or quality of life; overall quality of evidence was very low, though a positive trend was observed.

    Further high-quality RCTs are needed

    The policy identifies a group of procedures as experimental and investigational because their effectiveness for chronic pelvic pain or endometriosis has not been established. These listed procedures include dorsal root ganglion stimulation, hypogastric plexus neurolysis for chronic pelvic pain associated with endometriosis, peritoneal excision (stripping) for endometriosis, and uterine nerve ablation (UNA), laparoscopic uterine nerve ablation (LUNA), and presacral neurectomy (PSN). As such, these procedures are excluded from coverage under this policy.

    Surgical intervention for superficial peritoneal endometriosis depends on symptom status. The guideline-based recommendation is that surgical treatment of asymptomatic superficial peritoneal endometriosis is not recommended in women of child-bearing age for prevention of pelvic pain because there is no evidence the disease will progress to symptomatic disease. Likewise, routine adhesiolysis for incidental adhesions in asymptomatic patients is not recommended due to lack of demonstrated benefit and potential for surgical harm; decisions about adhesiolysis should be made case-by-case (for example, limited tubo-ovarian adhesions in infertile women may be considered).

    Prophylactic removal of superficial peritoneal endometriosis when lesions are asymptomatic is not supported by available evidence and therefore is not routinely recommended. The CNGOF guidance specifically advises against prophylactic excision of incidental superficial lesions in women of child-bearing age, while recommending excision only when lesions are surgically accessible and the patient is symptomatic. Routine prophylactic adhesiolysis to prevent pain or infertility in asymptomatic patients is likewise not supported.

    Large randomized trials and systematic reviews have shown that laparoscopic uterine nerve ablation (LUNA) does not provide consistent benefit for chronic pelvic pain. Cochrane and other systematic reviews concluded that evidence does not support LUNA for dysmenorrhea or chronic pelvic pain, and the large, blinded RCT by Daniels et al (487 patients) found no significant improvement in pain or quality of life with LUNA versus laparoscopy without denervation.

    Based on randomized trials, systematic reviews, and expert reviews, laparoscopic uterosacral nerve ablation (LUNA) is considered not effective for treatment of chronic pelvic pain related to endometriosis. Published evidence indicates no meaningful improvement in pain or quality-of-life outcomes with LUNA compared with surgery alone, and authoritative reviews state that LUNA is not shown to be effective.

    Systematic or routine adhesiolysis and removal of asymptomatic superficial peritoneal endometriosis solely to prevent future pelvic pain or infertility is not supported by current evidence. Guidelines and evidence reviews recommend against routine removal of incidental superficial lesions and advise that adhesiolysis to prevent pain or infertility should generally be avoided in asymptomatic patients, with case-by-case exceptions for limited tubo-ovarian adhesions in infertile women.

    Related Procedure and Diagnosis Codes

    Related CPT / HCPCS codes referencedmixed
    63650Percutaneous implantation of neurostimulator electrode array, epidural.
    63655Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
    63663Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
    63664Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed.
    63685Insertion or replacement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling.
    63688Revision or removal of implanted spinal neurostimulator pulse generator or receiver.
    64680Destruction by neurolytic agent, with or without radiologic monitoring; celiac plexus.
    64681Destruction by neurolytic agent, with or without radiologic monitoring; superior hypogastric plexus.
    95970Electronic analysis of implanted neurostimulator pulse generator system; without reprogramming.
    95971Electronic analysis of implanted neurostimulator pulse generator/transmitter, with programming.
    1–10 of 12
    1/2
    ICD-10 codes mentioned (examples from document)ICD-10
    N80.0 - N80.DEndometriosis (ICD-10 range listed in policy).
    R10.0 - R10.13 R10.30 - R10.33 R10.84Abdominal, pelvic and perineal pain.
    N94.0 - N94.9Pain and other conditions associated with female genital organs and menstrual cycle.

    Prior Authorization, Documentation, and Denial Risk

    Prior Authorization

    Prior Authorization Required for Specified Procedures/Devices

    Prior authorization is required for neurostimulation device procedures and related implantation/revision codes listed below. Submit a preauthorization request when considering spinal or dorsal root ganglion neuromodulation for chronic pelvic pain.

    • Prior authorization required for CPT codes: 63650, 63655, 63663, 63664, 63685, 63688, 95970, 95971.
    • Prior authorization recommended for HCPCS/CPT codes related to neurolytic procedures of pelvic plexuses (e.g., 64680, 64681).
    Prior Authorization

    Prior Authorization Likely for DRGS and Advanced Neuromodulation

    Dorsal root ganglion stimulation (DRGS) and other advanced neuromodulation approaches for chronic pelvic pain frequently require prior authorization; coverage is limited and clinical evidence is evolving. Consider case-by-case review for patients refractory to conservative care.

    • DRGS candidates should have documentation of failure of conservative therapies and multidisciplinary evaluation.
    • Preauthorization likely for sacral or DRG neuromodulation procedures (implantation, revision, generator placement).

    Clinical Background

    Chronic pelvic pain (CPP) is defined as persistent, non-cyclic pelvic pain lasting at least 6 months. It affects an estimated 15–20% of women aged 18–50. Endometriosis is a common gynecologic cause of CPP, but other causes include pelvic inflammatory disease, pelvic congestion, nerve entrapment, interstitial cystitis, and pelvic floor dysfunction. Management is individualized based on cause, symptom severity, fertility desires, and age, with first-line options including conservative medical therapy (NSAIDs, oral contraceptives), second-line pharmacologic agents (danazol, GnRH analogs), and conservative surgical approaches; hysterectomy is reserved for refractory cases.

    Definitions and Procedure Descriptions

    inv-32: Laparoscopic uterine nerve ablation (LUNA)
    DefinitionDestruction of uterine nerve fibers that exit the uterus through the uterosacral ligament, typically performed laparoscopically.
    Typical settingOften performed adjunctively during surgical treatment for endometriosis as a nerve-transection procedure.
    Evidence summaryRandomized trials and systematic reviews show limited or inconsistent benefit; large RCTs (e.g., Daniels et al) do not support effectiveness for chronic pelvic pain.
    Coverage stanceNot considered effective for chronic pelvic pain related to endometriosis; listed as experimental/investigational in this policy.
    inv-33: Presacral neurectomy (PSN)
    DefinitionInterruption of sympathetic innervation of the uterus at the level of the superior hypogastric plexus (presacral region).
    Policy Summary
    PayerAetna
    PolicyChronic Pelvic Pain, Endometriosis, and Other Indications: Selected Treatments
    Policy CodePolicy 0754
    Change TypeNo material change
    Effective DateMay 9, 2008
    Last ReviewOct 5, 2023
    Next Review DateAug 8, 2024
    Key ActionDocument trial and failure of conservative therapies (medical therapy, physical therapy, behavioral interventions) before requesting surgical or device-based interventions.
    SourceLink
    On This Page
    Coverage Criteria and Evidence SummaryRelated Procedure and Diagnosis CodesPrior Authorization, Documentation, and Denial RiskClinical BackgroundDefinitions and Procedure Descriptions
    Denial Risk

    Denial Risk — Experimental / Investigational Procedures

    Procedures identified as experimental or investigational are not covered. Expect denial when these are billed for chronic pelvic pain or endometriosis because effectiveness has not been established.

    • Claims for DRGS, hypogastric plexus neurolysis, peritoneal excision (stripping) for endometriosis, UNA/LUNA, and PSN may be denied as experimental/investigational.
    • Deny when submitted evidence does not meet medical necessity or when the procedure is explicitly labeled experimental in policy.
    Denial Risk

    Denial Risk — Procedures with Limited Evidence

    Certain nerve-dividing surgeries and presacral neurectomy have limited and inconsistent evidence of benefit; these procedures carry a higher denial risk when used for chronic pelvic pain or endometriosis.

    • Presacral neurectomy (PN/PSN) and other nerve‑dividing procedures may be denied or require strong supporting documentation due to limited evidence and potential harms (e.g., postoperative constipation).
    • Peritoneal excision (stripping) for endometriosis may be considered in select circumstances but is not uniformly supported; review clinical details carefully.
    Documentation Required

    Coding and Documentation Guidance

    Provide complete coding and operative details to facilitate review. When billing for neuromodulation or neurolytic procedures, include the specific CPT/HCPCS codes, device model (if applicable), and relation to pelvic pain diagnosis.

    • Include CPT codes: 63650, 63655, 63663, 63664, 63685, 63688, 95970, 95971, 64680, 64681 where applicable.
    • If there is no specific code (e.g., UNA/LUNA/PSN), clearly describe the procedure performed, operative approach, and rationale; consider unlisted procedure coding with operative report attached.
    Documentation Required

    Required Supporting Clinical Documentation for Prior Authorization

    Preauthorization and medical necessity reviews require detailed supporting documentation showing a stepwise treatment approach and failure of conservative therapies before advanced or surgical interventions.

    • Document trial and failure of conservative medical therapy (NSAIDs, oral contraceptives, progestins, GnRH analogs, other second‑line pharmacologics) with dates and response.
    • Document non‑surgical interventions attempted: pelvic floor physical therapy, behavioral therapy, other modalities and duration.
    • Provide multidisciplinary evaluation notes (gynecology, pain management, physical therapy, psychiatry/psychology as indicated).
    • Include pain diary, imaging (ultrasound), laparoscopy findings if performed, and prior operative reports when applicable.
    Step Therapy

    Stepwise Care and Step Therapy Preference for Conservative Treatments

    Conservative medical therapy and stepwise care are expected before surgical options. Prior authorization reviews will assess whether less invasive treatments were tried and documented.

    • Stepwise care should include first-line treatments: NSAIDs and hormonal therapy (oral contraceptives) for endometriosis.
    • Second-line pharmacologic trials (danazol, GnRH analogs, aromatase inhibitors) and documented response or intolerance are expected prior to considering surgery/neuromodulation.
    • Pelvic floor physical therapy and behavioral interventions should be trialed when indicated.
    • Hysterectomy considered only after failed conservative measures and when clinically appropriate.
    Technical noteTechnically more challenging than LUNA due to proximity of large vessels and the ureters near the dissection field.
    Evidence summarySome RCTs and meta-analysis suggest possible benefit for midline pain when combined with conservative surgery, but data are older and variable in quality.
    Safety signalAssociated with increased postoperative constipation (meta-analysis: 12.5% with PN vs 0% in controls).
    Coverage stanceConsidered experimental/investigational in policy; use only after conservative therapies and with informed selection—prior authorization recommended for adjunctive PN.
    inv-34: Chronic pelvic pain (CPP)
    DefinitionPersistent, non-cyclic pain perceived to be in structures related to the pelvis and lasting more than 6 months.
    Associated conditionsOften coexists with irritable bowel syndrome, chronic fatigue, and mental health disorders (e.g., depression, PTSD).
    Diagnostic approachDiagnosis based on history and physical exam; pelvic ultrasound to rule out anatomic causes; laparoscopy for suspected endometriosis when indicated.
    Initial managementBiopsychosocial approach with conservative medical therapy (NSAIDs, hormonal agents, gabapentin, GnRH agonists), pelvic floor physical therapy, and behavioral therapy before considering invasive interventions.
    inv-35: Presacral neurectomy (PN / PSN / LPSN)
    DefinitionSurgical targeting of presacral nerve fibers (PN/PSN/LPSN) intended to relieve midline pelvic pain when performed adjunctively with conservative endometriosis surgery.
    Evidence summaryMeta-analysis (7 studies, 503 women) showed lower treatment failure with PN (15.0%) versus controls (40.9%) over median 34 months, but studies were older and variable quality.
    Adverse eventsIncreased postoperative constipation reported (12.5% with PN).
    Clinical recommendationConsider only after failure of conservative surgery and medical therapy; benefits should be weighed against limited/heterogeneous evidence and potential complications.
    inv-36: Superior/inferior hypogastric plexus neurolysis/block
    DefinitionNeurolytic or anesthetic blockade of pelvic autonomic nerve plexuses (superior or inferior hypogastric plexus) intended to reduce pelvic visceral pain.
    Primary evidence baseEvidence mainly from cancer-related pelvic pain series (e.g., superior hypogastric plexus studies showing short- to medium-term benefit), not robust for endometriosis-related CPP.
    Reported outcomesSingle-center series reported success rates of ~59.4% at 1 month, 55.5% at 3 months, and 48.8% at 6 months for superior hypogastric plexus block in cancer patients.
    Coverage stanceConsider only for select refractory non-malignant cases after failure of conservative therapies and in specialized centers; considered experimental/investigational for CPP associated with endometriosis.
    inv-37: Superficial peritoneal endometriosis
    DefinitionEndometriotic lesions located on the peritoneal surface; may be symptomatic or entirely asymptomatic.
    IndicationsExcision or ablation of symptomatic superficial peritoneal endometriosis is recommended to improve pain and quality of life when lesions are accessible.
    Not recommendedSurgical treatment of asymptomatic superficial peritoneal endometriosis or prophylactic removal is not recommended in women of child-bearing age to prevent pelvic pain.
    Fertility considerationIn infertile women, excision is preferred over coagulation/ablation as it may result in higher spontaneous pregnancy rates (low level evidence).
    inv-38: Dorsal root ganglion stimulation (DRGS)
    DefinitionNeuromodulation technique that targets the dorsal root ganglion to treat chronic pelvic pain by modulating sensory signaling.
    Evidence summarySystematic review of 9 studies (65 patients) reported most implanted subjects had >50% mean pain reduction, but overall evidence quality is low (Level IV).
    Clinical considerationMay be considered on a case-by-case basis for patients with CPP refractory to non-interventional measures and not candidates for other neuromodulation.
    Policy stanceListed as experimental/investigational due to lack of high-quality supportive evidence; prior authorization recommended when requested.